Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study of subcutaneous ALKS 4230

Trial Profile

Phase 1 study of subcutaneous ALKS 4230

Phase of Trial: Phase I

Latest Information Update: 30 Oct 2018

At a glance

  • Drugs ALKS 4230 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Oct 2018 New trial record
    • 23 Oct 2018 According to an Alkermes Plc media release, IND has been submitted and this trial is expected to begin in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top